MX2012003201A - Composiciones y metodos para tratar infecciones bacterianas utilizando ceftarolina. - Google Patents

Composiciones y metodos para tratar infecciones bacterianas utilizando ceftarolina.

Info

Publication number
MX2012003201A
MX2012003201A MX2012003201A MX2012003201A MX2012003201A MX 2012003201 A MX2012003201 A MX 2012003201A MX 2012003201 A MX2012003201 A MX 2012003201A MX 2012003201 A MX2012003201 A MX 2012003201A MX 2012003201 A MX2012003201 A MX 2012003201A
Authority
MX
Mexico
Prior art keywords
ceftaroline
compositions
methods
bacterial infections
treat bacterial
Prior art date
Application number
MX2012003201A
Other languages
English (en)
Inventor
Dirk Thye
George Talbot
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43757152&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2012003201(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of MX2012003201A publication Critical patent/MX2012003201A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00Preparations for use in therapy
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cephalosporin Compounds (AREA)

Abstract

La presente invención se refiere a composiciones que comprenden ceftarolina o un profármaco de esta (p. ej., ceftarolina fosamilo) y métodos para tratar infecciones bacterianas, tales como infecciones complicadas de la piel y sus estructuras (cSSSI), y la neumonía bacteriana adquirida en la comunidad (CABP), administrando ceftarolina o un profármaco de esta (p. ej ., ceftarolina fosamilo).
MX2012003201A 2009-09-21 2010-09-21 Composiciones y metodos para tratar infecciones bacterianas utilizando ceftarolina. MX2012003201A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24412009P 2009-09-21 2009-09-21
US29490110P 2010-01-14 2010-01-14
PCT/US2010/049659 WO2011035305A1 (en) 2009-09-21 2010-09-21 Compositions and methods for treating bacterial infections using ceftaroline

Publications (1)

Publication Number Publication Date
MX2012003201A true MX2012003201A (es) 2012-05-08

Family

ID=43757152

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2012003201A MX2012003201A (es) 2009-09-21 2010-09-21 Composiciones y metodos para tratar infecciones bacterianas utilizando ceftarolina.
MX2012003411A MX2012003411A (es) 2009-09-21 2010-09-21 Composiciones y metodos para tratar infecciones bacterianas utilizando ceftarolina.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2012003411A MX2012003411A (es) 2009-09-21 2010-09-21 Composiciones y metodos para tratar infecciones bacterianas utilizando ceftarolina.

Country Status (24)

Country Link
US (2) US20110071114A1 (es)
EP (1) EP2480236A4 (es)
KR (1) KR20120083344A (es)
CN (1) CN102781451A (es)
AU (1) AU2010295269B2 (es)
BR (1) BR112012006250B1 (es)
CA (1) CA2774772A1 (es)
CL (1) CL2012000694A1 (es)
CO (1) CO6531417A2 (es)
CR (1) CR20120137A (es)
CU (1) CU20120048A7 (es)
DO (1) DOP2012000077A (es)
EA (1) EA029149B1 (es)
EC (1) ECSP12011739A (es)
GT (1) GT201200082A (es)
HN (1) HN2012000585A (es)
IL (1) IL218349A0 (es)
MX (2) MX2012003201A (es)
NI (1) NI201200045A (es)
PE (2) PE20121819A1 (es)
PH (1) PH12012500528A1 (es)
SG (1) SG178936A1 (es)
WO (1) WO2011035305A1 (es)
ZA (1) ZA201202924B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2951171A1 (fr) 2009-10-09 2011-04-15 Novexel Nouveau sel de sodium d'un compose azabicyclique sous forme enantiomere cristallisee et nouvelles formes polymorphes et pseudopolymorphes ainsi que leur preparation
RU2610091C2 (ru) 2011-06-17 2017-02-07 Астразенека Аб (2S,5R)-5-[(бензилокси)амино]пиперидин-2-карбоксамид
CN107621512B (zh) * 2017-11-02 2020-07-31 扬子江药业集团有限公司 一种柱前衍生化法测定头孢洛林酯侧链酰氯纯度的方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW473479B (en) * 1997-12-19 2002-01-21 Takeda Chemical Industries Ltd Phosphonocephem derivatives, their production and use
DK1310502T3 (da) * 2000-08-10 2009-09-07 Takeda Pharmaceutical Phosphonocephem-forbindelse
US20030186339A1 (en) * 2001-05-17 2003-10-02 Mcgill University Individualization of therapy with antibiotic agents
EP2316468A1 (en) * 2002-02-22 2011-05-04 Shire LLC Delivery system and methods for protecting and administering dextroamphetamine
JP2010540448A (ja) * 2007-09-21 2010-12-24 フォレスト・ラボラトリーズ・ホールディングス・リミテッド 非経口投与に適したセフェム誘導体を含む可溶製剤

Also Published As

Publication number Publication date
AU2010295269B2 (en) 2014-06-05
CN102781451A (zh) 2012-11-14
PE20171176A1 (es) 2017-08-22
CR20120137A (es) 2012-05-28
DOP2012000077A (es) 2012-05-31
EA201200501A1 (ru) 2012-10-30
CU20120048A7 (es) 2012-10-15
CL2012000694A1 (es) 2012-08-31
ZA201202924B (en) 2012-12-27
US9629861B2 (en) 2017-04-25
IL218349A0 (en) 2012-04-30
US20110071114A1 (en) 2011-03-24
MX2012003411A (es) 2012-04-30
CA2774772A1 (en) 2011-03-24
BR112012006250A2 (pt) 2016-05-31
EA029149B1 (ru) 2018-02-28
NI201200045A (es) 2012-11-02
BR112012006250B1 (pt) 2021-07-06
US20150258126A1 (en) 2015-09-17
EP2480236A4 (en) 2013-04-17
WO2011035305A1 (en) 2011-03-24
AU2010295269A1 (en) 2012-04-12
CO6531417A2 (es) 2012-09-28
EP2480236A1 (en) 2012-08-01
HN2012000585A (es) 2015-06-15
PE20121819A1 (es) 2013-02-01
KR20120083344A (ko) 2012-07-25
PH12012500528A1 (en) 2019-06-14
ECSP12011739A (es) 2012-05-30
SG178936A1 (en) 2012-04-27
GT201200082A (es) 2014-12-22

Similar Documents

Publication Publication Date Title
CL2013002517A1 (es) Compuestos derivados de fosforoamidato de 5-fluoro-2'-desoxiuridina; procedimiento de preparacion; composicion farmaceutica que los comprende; su uso en el tratamiento o profilaxis del cancer.
UY32456A (es) Composicion famaceutica, forma farmaceutica, procedimiento para su preparación, metodos de tratamiento
CR20120264A (es) Compuestos
CR20110407A (es) Dicianopiridinas alquilamino-sustituidas y sus profármacos de éster de aminoácido
PA8819201A1 (es) Derivados de azetidina y ciclobutano como inhibidores de jak
ECSP11011276A (es) Composición farmacéutica, forma farmacéutica, procedimiento para su preparación, métodos de tratamiento y usos de la misma.
NI201100082A (es) Compuestos de isoindolina para uso en el tratamiento de cáncer.
CR20110509A (es) Composicion farmaceutica
UY35391A (es) Acido 2-aza-biciclo[2.2.1]heptano-3-carboxilico (bencil-cianometil)-amidas sustituidas inhibidores de catepsina c
BR112016012862A2 (pt) formulações para vacinas para neoplasia
CR20110558A (es) ANTICUERPOS ANTI-FcRH5 E INMUNOCONJUGADOS Y MÉTODOS DE USO
BR112012020693A8 (pt) Derivados de ciclobutano e metilciclobutano como inibidores de janus quinase e composição que os compreende
GT201200016A (es) Derivados de oxazina y su uso como inhibidores de bace para el tratamiento de trastornos neurológicos
CR11731A (es) Composiciones y procedimientos para su preparación y uso
CR20120510A (es) Derivados de piperidin-4-il azetidina como inhibidores de jak1
GT201400097A (es) Agentes de iarn, composiciones y métodos de uso de los mismos para tratar enfermedades asociadas con transtiretina (ttr)
BR112012019302A2 (pt) imidazo[1,2-b][1,2,4]triazinas como inibidores de c-met
HN2011003011A (es) Composiciones sublinguales de dexmedetomidina y metodos de uso de ellas
EA201170832A1 (ru) Пуриновые соединения
CL2017003066A1 (es) Composiciones de carbonato de calcio amorfo para administración mediante inhalación, sublingual o bucal
BR112013000776A2 (pt) método e formulação para tratamento de deficiência de ácido siálico
CR20130602A (es) Compuestos novedosos como inhibidores de diacilglicerol aciltransferasa
BR112012014760A2 (pt) "composições orgânicas para tratar doenças relacionadas a hsf1, bem como seu uso"
BR112012019920A2 (pt) derivados de piridazina úteis como agonístas de canabinoide-2.
BR112014026817A2 (pt) derivados do pantotenato para o tratamento de transtornos neurológicos

Legal Events

Date Code Title Description
FA Abandonment or withdrawal